Site search
2880 results for '' found
Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to S
Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to S
/
A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose [AER-01] Inhalation Solution in the Treatment of Adu
A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose [AER-01] Inhalation Solution in the Treatment of Adu
/
A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients (ADVANCE-outcomes) (NCT03626688)
A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients (ADVANCE-outcomes) (NCT03626688)
/
A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION (ADVANCE-extension) (NCT03683186)
A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION (ADVANCE-extension) (NCT03683186)
/
An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage II
An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage II
/
A beta-lactam antibiotic Dose Adaptation Pilot randomised controlled Trial utilising Therapeutic Drug Monitoring (ADAPT-TDM) (ACTRN12623000032651)
A beta-lactam antibiotic Dose Adaptation Pilot randomised controlled Trial utilising Therapeutic Drug Monitoring (ADAPT-TDM) (ACTRN12623000032651)
/
A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients with Advanced Solid Tumors (NCT06336148)
A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients with Advanced Solid Tumors (NCT06336148)
/
Feasibility Study of the Vessel Restoration System 〈VRS〉 for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA): ACTIVATE II (
Feasibility Study of the Vessel Restoration System 〈VRS〉 for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA): ACTIVATE II (
/
A study of the safety and feasibility of the Vessel Restoration System for AVF to promote the physiologic and functional maturation of upperextremity autologous End-to-Side Arteriovenous Fistulas
A study of the safety and feasibility of the Vessel Restoration System for AVF to promote the physiologic and functional maturation of upperextremity autologous End-to-Side Arteriovenous Fistulas
/